Redeye provides a research update following the Q4 report published by OncoZenge earlier today.
Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with Yan...
Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-led patient engagement study for BupiZenge...
Redeye leaves a comment following OncoZenge’s announcement of a SEK5m bridge financing via a convertible note with Linc and the formal payme...
Redeye leaves a comment following OncoZenge’s announcement regarding the delayed payment of tranche 3 from the investment agreement with Yan...
Redeye leaves a comment following OncoZenge’s announcement of having submitted the Clinical Trial Application for its pivotal phase III tria...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study fo...
Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an important first step toward a potential ...
Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge.
Redeye provides a research update following the Q2 report published by OncoZenge earlier today.
Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici, which accelerates EUR550,000 in milest...
Redeye comments on OncoZenge’s announcement of a SEK7.
Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.
Redeye comments on OncoZenge’s engagement of LINK Medical to conduct a feasibility study ahead of its European phase III trial for BupiZenge...
Redeye provides a research update following the Q1 report published by OncoZenge earlier today.
Redeye comments on OncoZenge’s announcement of an exclusive licensing agreement with Avernus Pharma for the commercialization of BupiZenge i...
Redeye leaves a comment following OncoZenge’s announcement of having finalized a binding partnership agreement with specialty pharmaceutical...
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered a SEK30.
Redeye leaves a comment following OncoZenge’s announcement yesterday of having entered into a non-binding partnership agreement with special...
Redeye provides a research update following the Pharmanovia’s decision to discontinue the partnership with OncoZenge and not sign a definite...
Redeye leaves a comment following today’s announcement by OncoZenge stating that Pharmanovia has decided to refrain from signing a binding d...
Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution to the USD1.
Inga överraskningar – fortsatt låg kostnadsbas att vänta OncoZenges rapport för det fjärde kvartalet inkluderade inga överraskningar.
OncoZenge meddelade i fredags en strategiuppdatering avseende deras läkemedelskandidat BupiZenge.
Rapportkommentar OncoZenge släppte under förra veckan sin rapport för det tredje kvartalet.
Fortsatt fokus på BupiZenge OncoZenge levererade nyligen sin rapport för det andra kvartalet.
Pausar utvecklingen av BupiZenge OncoZenge meddelande under onsdagen att bolaget pausar utvecklingen av BupiZenge.
En rapport i linje med våra förväntningar OncoZenge rapport för det första kvartalet var i linje med våra förväntningar.
Rapportkommentar OncoZenge presenterade under gårdagen sin rapport för det fjärde kvartalet.
Kvartalets händelser OncoZenge presenterade under gårdagen sin rapport för det tredje kvartalet.
Q2-rapport OncoZenge presenterade under gårdagen sin rapport för det andra kvartalet.
Rapportkommentar Under tisdagen presenterade OncoZenge sin rapport för det första kvartalet, vilken var i linje med våra förväntningar.
Avbryter planerad studie OncoZenge meddelade idag att bolaget avbryter den planerade farmakokinetiska studien med BupiZenge.
Inga överraskningar Oncozenge presenterade igår sin rapport för det fjärde kvartalet.
Inga överraskningar i Q3-rapporten OncoZenge släppte under tisdagen sin rapport för det tredje kvartalet.
Kostnaderna under förväntan Omsättningen uppgick som väntat till 0 mkr under Q2'21.
